CD274 and breast carcinoma: Among breast cancer subtypes, TNBC exhibit higher tumor mutational burden (TMB), tumor infiltrates of lymphocytes (TILs) and PD-L1 expression, indicating its candidacy for immune checkpoint inhibition therapy (6–8).